Geneva and Tel Aviv, July 21, 2021: Unilabs, a leading international provider of diagnostic services, and Ibex Medical Analytics, the pioneer in artificial intelligence-powered cancer diagnostics, have agreed on a deal to implement Ibex’s AI platform in Europe. Starting with a national roll out in Sweden, Unilabs will then roll the platform out across all of its sixteen countries.
Unilabs is the first pan-European diagnostics provider to deploy Ibex’s multi-tissue AI-powered Galen™ platform, providing patients and physicians with a faster and more accurate diagnosis, facilitating prompt, targeted cancer treatment when it is most needed.
“This cutting-edge AI technology will help our teams quickly prioritise urgent cases, speed up diagnosis, and improve quality by adding an extra set of digital eyes,” said Dr. Christian Rebhan, Unilabs’ Chief Medical & Operations Officer. “When it comes to cancer, the earlier you catch it, the better the prognosis – so getting us critical results faster will help save lives. The partnership with Ibex underlines Unilabs’ pioneering role in Digital Pathology and represents yet another step in our ambition to become the most digitally enabled provider of diagnostic services in Europe.”
“Ibex is transforming cancer diagnosis with innovative AI solutions across the diagnostic pathway," said Joseph Mossel, Chief Executive Officer and Co-Founder of Ibex Medical Analytics. "We are excited to partner with Unilabs to deploy our AI solutions and empower their pathologists with faster turnaround times and quality diagnosis. This cooperation follows a thorough evaluation of our technology at Unilabs and demonstrates the robustness and utility of our platform for everyday clinical practice".
Using algorithms developed with advanced machine learning, the Galen platform is trained to detect cancer and other clinical findings. The algorithms automatically analyse images from tissue biopsies, providing insights to pathologists who diagnose the case and whose assessment is vital for reaching correct treatment decisions by oncologists. These AI-generated insights include case prioritisation worklists, cancer heatmaps, tumour grading and measurement, streamlined reporting tools and more.
Ibex transforms cancer diagnosis by harnessing Strong AI and machine learning technology at an unprecedented scale. Ibex's Galen platform helps pathologists improve the quality of cancer diagnosis, implement real-time quality control, reduce diagnosis time, and boost productivity. It is CE marked for breast and prostate cancer detection in multiple workflows and was recently granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). Galen has already demonstrated outstanding outcomes in clinical studies and has been deployed in leading laboratories worldwide, where it is used as part of everyday clinical practice.